SMTI

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)

Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter

FORT

WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Summary(1)

●Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025.

●Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net revenue, in the first quarter of 2025.

●Operating income of $2.6 million, compared to operating income of $0.8 million in the first quarter of 2025.

●Net income from continuing operations of $0.4 million, or $0.04 per diluted share, compared to net loss from continuing operations of $0.6 million, or $0.07 per diluted share, in the first quarter of 2025.

●Adjusted EBITDA(2) of $4.3 million, compared to $2.7 million in the first quarter of 2025.

●Cash of $13.6 million and $46.2 million of long-term debt at March 31, 2026, compared to $16.6 million of cash and $46.0 million of long-term debt at December 31, 2025.

(1) As a result of the Company’s strategic realignment, the operations of Tissue Health Plus (“THP”), which were previously reported as the THP segment, have been classified as discontinued operations in Sanara’s financial statements for the three months ended March 31, 2026 and 2025.

(2) Adjusted EBITDA is a non-GAAP financial measure. See the discussion and the reconciliation at the end of this release for additional information.

Management Comments

Seth Yon, President and Chief Executive Officer of Sanara, commented, “The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We’re particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down.

“During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps,” Mr. Yon stated. “Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than 450 distributors.

“Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth,” Mr. Yon concluded.

First Quarter of 2026 Revenue

The following table summarizes revenue streams from product sales for the three months ended March 31, 2026 and 2025:

Three Months Ended

March 31,

2026 2025

Soft tissue repair products $24,942,945 $20,532,440

Bone fusion products 2,855,589 2,901,656

Total Net Revenue $27,798,534 $23,434,096

First Quarter of 2026 Financial Results(1)

Net revenue for the first quarter of 2026 was $27.8 million, compared to $23.4 million for the first quarter of 2025, an increase of $4.4 million, or 19%, year-over-year. The increase in net revenue was driven by an increase of $4.4 million, or 21%, in sales of soft tissue repair products, offset by a slight decrease of $46,067, or 2%, in sales of bone fusion products. The increase in net revenue is primarily due to increased sales of soft tissue repair products, including CellerateRX® Surgical Powder and BIASURGE® Advanced Surgical Solution, supported by increased market penetration and geographic expansion, and the Company’s strategy to continue expanding and developing its independent distribution network in both new and existing U.S. markets.

Gross profit for the first quarter of 2026

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial

Results; Reaffirmed Full Year 2026 Financial Guidance

FORT

WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026.

Fourth Quarter 2025 Financial Summary(1)

●Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024.

○As previously disclosed, the Company experienced growth in sales of BIASURGE® Advanced Surgical Solution (“BIASURGE”) in the fourth quarter of 2024 as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. Excluding $1.8 million of BIASURGE sales related to this dynamic in the fourth quarter of 2024, net revenue in the fourth quarter of 2025 increased 13% year-over-year.(2)

●Net loss from continuing operations of $1.1 million, compared to net income from continuing operations of $0.9 million in the fourth quarter of 2024.

●Adjusted EBITDA(2) of $4.7 million, compared to $4.1 million in the fourth quarter of 2024.

Full Year 2025 Financial Summary(1)

●Net revenue increased 19% to $103.1 million, compared to $86.7 million in 2024.

○Excluding the aforementioned $1.8 million of BIASURGE sales in the fourth quarter 2024, net revenue for the full year 2025 increased 22% year-over-year.(2)

●Net loss from continuing operations of $0.4 million, compared to net loss from continuing operations of $1.9 million in 2024.

●Adjusted EBITDA(2) of $17.0 million, compared to $9.1 million in 2024.

Fourth Quarter 2025 and Recent Operational Announcements

●On December 10, 2025, the Company provided an update on progress related to its strategic alliance with Biomimetic Innovations Ltd (“BMI”). In addition, Sanara reaffirmed its plans to introduce the OsStic™ Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration, to support reduction and provisional fixation treatment of the more than 100,000(3) peri-articular fractures occurring annually nationwide.

●On January 7, 2026, the Company announced its BIASURGE product received an Innovative Technology contract from Vizient® Inc. (“Vizient”), the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of BIASURGE by hospital experts who serve on one of Vizient’s client-led councils, and it signifies to Vizient clients BIASURGE’s unique qualities that potentially bring improvement to the healthcare industry. The Innovative Technology contract offers Vizient’s extensive network of healthcare facility customers access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026.

●On March 11, 2026, the Company announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder (“CellerateRX Surgical”) in the Journal of Medical Economics. The study demonstrated cost savings and improved health outcomes associated with the use of CellerateRX Surgical as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone.

(1) As a result of the Company’s strategic realignment, the operations of Tissue Health Plus (“THP”), which were previously reported as the THP segment, have been classified as discontinued operations in Sanara’s financial statements for the three months and years ended December 31, 2025 and 2024.

(2) Net revenue excluding extraordinary BIASURGE sales in the fourth quarter of 2024 and Adjusted EBITDA are non-GAAP financial measures. See the discussion and the reconciliations at the end of this release for additional information.

(3) National Library of Medicine; BMI and Sanara company estimates.

Management Comments

“We are pleased to deliver strong sales performance in 2025, achieving our first full year of net revenue in excess of $100 million, with 19% growth year-over-year,” stated Seth Yon, Sanara’s President and Chief Executive Officer. “Our sales performance reflected impressive commercial execution by our field sales team, who continued to develop our distributor relationships, while educating potential surgeon customers in both new and existing healthcare facilities. As a result, we made notable progress in expanding our network of distributors, facility customers, and surgeon users. Importantly, we complemented our full ye